For 24 years, one of the most effective treatments in menopause care sat largely unused. Today, roughly 41 million women in the United States are between the ages of 45 and 64.1 About one in three experience moderate-to-severe vasomotor symptoms that meaningfully erode daily function.2 Yet as of 2020, only approximately 2 million had received a hormone therapy prescription — roughly 5% of all postmenopausal women, down from nearly 27% in 1999.3 That gap has a cause. Understanding it is the first step toward closing it.
To understand where we are today, it helps to understand what happened in 2002.
The Women’s Health Initiative was designed to evaluate the long-term health effects of hormone therapy in postmenopausal women, but its findings were more complicated than early reporting suggested.
Randomizing over 16,000 women to oral conjugated equine estrogen plus medroxyprogesterone acetate versus placebo, the trial found small absolute increases in cardiovascular events, stroke, pulmonary embolism, and breast cancer per 10,000 person-years, alongside reductions in colorectal cancer and hip fractures.4
Critically, the WHI enrolled a population substantially older than typical MHT candidates. The mean age was 63.3 years, only about one-third of participants were aged 50 to 59, and the trial disproportionately represented women well past the symptomatic menopausal transition for whom hormone therapy was never primarily indicated.4
A 26% relative risk increase in breast cancer, widely reported, translated to just 8 additional cases per 10,000 women annually. The headlines never made that distinction.4,5
The consequences were lasting. Boxed warnings followed, prescribing fell from nearly 27% to under 5% and never recovered,3 and a broad clinical assumption took hold: that MHT carried meaningful cancer risk across all formulations, all patient profiles, and all timing scenarios. That assumption persisted largely unchallenged in everyday practice for two decades.
A 2025 secondary analysis by Rossouw and colleagues would finally begin to challenge that picture, finding that women who initiated therapy closer to menopause onset had meaningfully different risk profiles than the older cohort that dominated the original trial.6
Timing, it turned out, mattered enormously.
The more productive question emerging from the WHI era was never simply whether MHT was safe or dangerous. It was: Safe or dangerous for whom, with what formulation, and when?
The evidence that followed points in a consistent direction. Cardiovascular effects depend critically on age, time since menopause, and underlying vascular health at initiation — a framework now widely described as the timing hypothesis.13 Women who initiate therapy within 10 years of menopause onset, or before age 60, show meaningfully different risk profiles than those who begin later, including reductions in coronary heart disease risk and all-cause mortality in appropriate candidates.6,13
Formulation carries equal weight. Oral estradiol undergoes hepatic first-pass metabolism, producing metabolites that may increase thrombotic risk. Transdermal estradiol bypasses this pathway, demonstrating lower venous thromboembolism (VTE) and stroke risk in observational studies.10 Progestogen choice matters as well, with micronized progesterone showing a more favorable risk profile than the medroxyprogesterone acetate used in the original WHI.10
For women with a personal history of hormone-sensitive cancer or those at elevated breast cancer risk, MHT requires careful individual risk assessment and is generally not recommended without specialist input.10,12
It was this accumulating body of evidence — on timing, formulation, and patient selection — that informed the FDA’s November 2025 decision to revise MHT labeling for the first time in over two decades.7 The boxed warnings for cardiovascular disease, breast cancer, and probable dementia were removed, and the longstanding directive to use the lowest dose for the shortest duration was replaced with guidance to consider initiating therapy in women under 60 or within 10 years of menopause onset.7,8 These changes reflect the FDA’s assessment that the evidence no longer supports the original warnings as written.5
Regulatory changes of this magnitude generate attention, and attention generates misinformation. As MHT re-enters mainstream clinical discourse, appropriate patient selection is not a footnote – it is the foundation.
Hot flashes are the most commonly reported menopause symptom, affecting up to 75% of women during the transition, though the overall symptom burden varies widely.11 For some women the experience is primarily vasomotor. For others it manifests as disrupted sleep, joint discomfort, mood changes, or genitourinary symptoms.
The evidence supports that effective treatment of these symptoms is associated with improvements in quality of life and the behaviors that sustain long-term health, including physical activity, sleep quality, and mental well-being.10,11 Viewed through a healthy aging lens, adequately managed menopause is not simply about symptom relief. It is about preserving the functional reserve that allows women to remain active, engaged, and well into the decades that follow.
The long-term signals reinforce this framing. Women who initiate MHT within 10 years of menopause onset show reductions in all-cause mortality and fracture risk.8 Keeping patients active, sleeping well, and mentally engaged in their fifties is, in measurable terms, how you support healthy aging into their seventies and beyond.
The economic consequences of untreated menopause, estimated at $1.8 billion annually in lost productivity alone, are real, but they are a symptom of a deeper problem.9 The problem is that a generation of women went undertreated.
The updated labeling and the supporting evidence converge on a consistent clinical picture. The question for prescribers is not whether MHT is back on the table. It is which patients belong at that table, and how best to have that conversation.
Current guidance from The Menopause Society identifies appropriate candidates as women under 60 or within 10 years of menopause onset, experiencing bothersome menopausal symptoms, and without contraindications.12
Formulation should be individualized. Transdermal estradiol is preferred when cardiometabolic or thromboembolic risk is a consideration, given its more favorable vascular profile compared to oral preparations. For women with an intact uterus, micronized progesterone is the preferred progestogen, with a more favorable metabolic profile than medroxyprogesterone acetate.10
Duration is no longer governed by an arbitrary treatment ceiling. Shared decision-making, the lowest effective dose, and periodic re-evaluation are the current standard.12 For appropriate candidates, continuing therapy as long as benefits outweigh risks is now explicitly supported.7
Above all, this is a conversation to have, not a prescription to defer. Shared decision-making requires clinicians equipped with accurate, current information. That is what the evidence now provides.
The narrative around menopausal hormone therapy is shifting, not because of advocacy, but because the evidence demanded it. For clinicians, that shift carries a practical implication – the guidance that discouraged MHT prescribing for two decades has been formally reassessed, and the clinical community now has the regulatory and evidentiary footing to revisit these conversations with patients.
The underuse of MHT represents a documented care gap, with measurable consequences for quality of life, long-term health, and preventable outcomes in women who were appropriate candidates and never offered treatment.
The label changes are meaningful but not a signal to prescribe broadly. Appropriate patient selection, shared decision-making, individualized formulation choices, ongoing monitoring, and regular reassessment of benefit and risk remain the standard of care.
For women experiencing bothersome menopausal symptoms, an informed, individualized clinical conversation is the most important first step.
The above content is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health providers with any questions about a medical condition.
© 2026 American Academy of Value-Based Care. All rights reserved.
